Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021
Shots:
- The interim analysis of open-label P- IIIb ENSEMBLE study of Ocrevus (ocrelizumab) showed 85% of patients achieved no evidence of disease activity in early-stage RRMS- low annualized relapse rate- improvement in EDSS score
- The post-hoc analysis of P-III ORATORIO study of Ocrevus vs PBO showed slow loss of brain tissue within T2 MRI lesions in PPMS @120wks.
- In a 2yrs. US claims analysis- 80% of patients with twice-yearly (6mos.) dosing of Ocrevus showed highest adherence and persistence rates vs other DMTs showed- 75% of patients persist with therapy @2yrs.
Ref: Business Wire | Image: Lassonde Entrepreneur Institute
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com